Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
The treatment landscape of metastatic urothelial cancer (mUC) remained unchanged for over 30 years until the approval of immune checkpoint inhibitors (ICIs) in 2016. Since then, several ICIs have been approved for the treatment of mUC. In addition, recent molecular characterization of bladder cancer...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publishing
2022-09-01
|
| Seri Bilgileri: | Clinical Medicine Insights: Oncology |
| Online Erişim: | https://doi.org/10.1177/11795549221126252 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|